Chapter/Section Purchase

1 Study Coverage
1.1 Influenza NA Inhibitor Product Introduction
1.2 Market by Type
1.2.1 Global Influenza NA Inhibitor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Zanamivir
1.2.3 Oseltamivir
1.2.4 Peramivir
1.3 Market by Application
1.3.1 Global Influenza NA Inhibitor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Influenza A Treatment
1.3.3 Influenza B Treatment
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Influenza NA Inhibitor Sales Estimates and Forecasts 2017-2028
2.2 Global Influenza NA Inhibitor Revenue Estimates and Forecasts 2017-2028
2.3 Global Influenza NA Inhibitor Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Influenza NA Inhibitor Sales by Region
2.4.1 Global Influenza NA Inhibitor Sales by Region (2017-2022)
2.4.2 Global Sales Influenza NA Inhibitor by Region (2023-2028)
2.5 Global Influenza NA Inhibitor Revenue by Region
2.5.1 Global Influenza NA Inhibitor Revenue by Region (2017-2022)
2.5.2 Global Influenza NA Inhibitor Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Influenza NA Inhibitor Sales by Manufacturers
3.1.1 Global Top Influenza NA Inhibitor Manufacturers by Sales (2017-2022)
3.1.2 Global Influenza NA Inhibitor Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Influenza NA Inhibitor in 2021
3.2 Global Influenza NA Inhibitor Revenue by Manufacturers
3.2.1 Global Influenza NA Inhibitor Revenue by Manufacturers (2017-2022)
3.2.2 Global Influenza NA Inhibitor Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Influenza NA Inhibitor Revenue in 2021
3.3 Global Influenza NA Inhibitor Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Influenza NA Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Influenza NA Inhibitor Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Influenza NA Inhibitor Sales by Type
4.1.1 Global Influenza NA Inhibitor Historical Sales by Type (2017-2022)
4.1.2 Global Influenza NA Inhibitor Forecasted Sales by Type (2023-2028)
4.1.3 Global Influenza NA Inhibitor Sales Market Share by Type (2017-2028)
4.2 Global Influenza NA Inhibitor Revenue by Type
4.2.1 Global Influenza NA Inhibitor Historical Revenue by Type (2017-2022)
4.2.2 Global Influenza NA Inhibitor Forecasted Revenue by Type (2023-2028)
4.2.3 Global Influenza NA Inhibitor Revenue Market Share by Type (2017-2028)
4.3 Global Influenza NA Inhibitor Price by Type
4.3.1 Global Influenza NA Inhibitor Price by Type (2017-2022)
4.3.2 Global Influenza NA Inhibitor Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Influenza NA Inhibitor Sales by Application
5.1.1 Global Influenza NA Inhibitor Historical Sales by Application (2017-2022)
5.1.2 Global Influenza NA Inhibitor Forecasted Sales by Application (2023-2028)
5.1.3 Global Influenza NA Inhibitor Sales Market Share by Application (2017-2028)
5.2 Global Influenza NA Inhibitor Revenue by Application
5.2.1 Global Influenza NA Inhibitor Historical Revenue by Application (2017-2022)
5.2.2 Global Influenza NA Inhibitor Forecasted Revenue by Application (2023-2028)
5.2.3 Global Influenza NA Inhibitor Revenue Market Share by Application (2017-2028)
5.3 Global Influenza NA Inhibitor Price by Application
5.3.1 Global Influenza NA Inhibitor Price by Application (2017-2022)
5.3.2 Global Influenza NA Inhibitor Price Forecast by Application (2023-2028)
6 North America
6.1 North America Influenza NA Inhibitor Market Size by Type
6.1.1 North America Influenza NA Inhibitor Sales by Type (2017-2028)
6.1.2 North America Influenza NA Inhibitor Revenue by Type (2017-2028)
6.2 North America Influenza NA Inhibitor Market Size by Application
6.2.1 North America Influenza NA Inhibitor Sales by Application (2017-2028)
6.2.2 North America Influenza NA Inhibitor Revenue by Application (2017-2028)
6.3 North America Influenza NA Inhibitor Market Size by Country
6.3.1 North America Influenza NA Inhibitor Sales by Country (2017-2028)
6.3.2 North America Influenza NA Inhibitor Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Influenza NA Inhibitor Market Size by Type
7.1.1 Europe Influenza NA Inhibitor Sales by Type (2017-2028)
7.1.2 Europe Influenza NA Inhibitor Revenue by Type (2017-2028)
7.2 Europe Influenza NA Inhibitor Market Size by Application
7.2.1 Europe Influenza NA Inhibitor Sales by Application (2017-2028)
7.2.2 Europe Influenza NA Inhibitor Revenue by Application (2017-2028)
7.3 Europe Influenza NA Inhibitor Market Size by Country
7.3.1 Europe Influenza NA Inhibitor Sales by Country (2017-2028)
7.3.2 Europe Influenza NA Inhibitor Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Influenza NA Inhibitor Market Size by Type
8.1.1 Asia Pacific Influenza NA Inhibitor Sales by Type (2017-2028)
8.1.2 Asia Pacific Influenza NA Inhibitor Revenue by Type (2017-2028)
8.2 Asia Pacific Influenza NA Inhibitor Market Size by Application
8.2.1 Asia Pacific Influenza NA Inhibitor Sales by Application (2017-2028)
8.2.2 Asia Pacific Influenza NA Inhibitor Revenue by Application (2017-2028)
8.3 Asia Pacific Influenza NA Inhibitor Market Size by Region
8.3.1 Asia Pacific Influenza NA Inhibitor Sales by Region (2017-2028)
8.3.2 Asia Pacific Influenza NA Inhibitor Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Influenza NA Inhibitor Market Size by Type
9.1.1 Latin America Influenza NA Inhibitor Sales by Type (2017-2028)
9.1.2 Latin America Influenza NA Inhibitor Revenue by Type (2017-2028)
9.2 Latin America Influenza NA Inhibitor Market Size by Application
9.2.1 Latin America Influenza NA Inhibitor Sales by Application (2017-2028)
9.2.2 Latin America Influenza NA Inhibitor Revenue by Application (2017-2028)
9.3 Latin America Influenza NA Inhibitor Market Size by Country
9.3.1 Latin America Influenza NA Inhibitor Sales by Country (2017-2028)
9.3.2 Latin America Influenza NA Inhibitor Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Influenza NA Inhibitor Market Size by Type
10.1.1 Middle East and Africa Influenza NA Inhibitor Sales by Type (2017-2028)
10.1.2 Middle East and Africa Influenza NA Inhibitor Revenue by Type (2017-2028)
10.2 Middle East and Africa Influenza NA Inhibitor Market Size by Application
10.2.1 Middle East and Africa Influenza NA Inhibitor Sales by Application (2017-2028)
10.2.2 Middle East and Africa Influenza NA Inhibitor Revenue by Application (2017-2028)
10.3 Middle East and Africa Influenza NA Inhibitor Market Size by Country
10.3.1 Middle East and Africa Influenza NA Inhibitor Sales by Country (2017-2028)
10.3.2 Middle East and Africa Influenza NA Inhibitor Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Green Cross
11.1.1 Green Cross Corporation Information
11.1.2 Green Cross Overview
11.1.3 Green Cross Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Green Cross Influenza NA Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Green Cross Recent Developments
11.2 Roche
11.2.1 Roche Corporation Information
11.2.2 Roche Overview
11.2.3 Roche Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Roche Influenza NA Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Roche Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Corporation Information
11.3.2 GlaxoSmithKline Overview
11.3.3 GlaxoSmithKline Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 GlaxoSmithKline Influenza NA Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 GlaxoSmithKline Recent Developments
11.4 Henan DaKen Chemical
11.4.1 Henan DaKen Chemical Corporation Information
11.4.2 Henan DaKen Chemical Overview
11.4.3 Henan DaKen Chemical Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Henan DaKen Chemical Influenza NA Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Henan DaKen Chemical Recent Developments
11.5 ATK Chemical
11.5.1 ATK Chemical Corporation Information
11.5.2 ATK Chemical Overview
11.5.3 ATK Chemical Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 ATK Chemical Influenza NA Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 ATK Chemical Recent Developments
11.6 Chemwill Asia Co.,Ltd.
11.6.1 Chemwill Asia Co.,Ltd. Corporation Information
11.6.2 Chemwill Asia Co.,Ltd. Overview
11.6.3 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Chemwill Asia Co.,Ltd. Recent Developments
11.7 Shionogi Co.
11.7.1 Shionogi Co. Corporation Information
11.7.2 Shionogi Co. Overview
11.7.3 Shionogi Co. Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Shionogi Co. Influenza NA Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Shionogi Co. Recent Developments
11.8 NeoPharm
11.8.1 NeoPharm Corporation Information
11.8.2 NeoPharm Overview
11.8.3 NeoPharm Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 NeoPharm Influenza NA Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 NeoPharm Recent Developments
11.9 Moksha8 Pharma
11.9.1 Moksha8 Pharma Corporation Information
11.9.2 Moksha8 Pharma Overview
11.9.3 Moksha8 Pharma Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Moksha8 Pharma Influenza NA Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Moksha8 Pharma Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Influenza NA Inhibitor Industry Chain Analysis
12.2 Influenza NA Inhibitor Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Influenza NA Inhibitor Production Mode & Process
12.4 Influenza NA Inhibitor Sales and Marketing
12.4.1 Influenza NA Inhibitor Sales Channels
12.4.2 Influenza NA Inhibitor Distributors
12.5 Influenza NA Inhibitor Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Influenza NA Inhibitor Industry Trends
13.2 Influenza NA Inhibitor Market Drivers
13.3 Influenza NA Inhibitor Market Challenges
13.4 Influenza NA Inhibitor Market Restraints
14 Key Findings in The Global Influenza NA Inhibitor Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer